A Randomized, Double-blind, Two-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of Adalimumab (TUR01 and EU Sourced Humira®) in Healthy Subjects
This is a randomized, double-blind, two-arm, parallel group, single-dose study to demonstrate pharmacokinetic, safety, tolerability and immunogenicity similarity of biosimilar candidate TUR01 to EU-sourced Humira® in healthy participants after administration of adalimumab.
100 Clinical Results associated with Turgut İlaçları A.Ş.
0 Patents (Medical) associated with Turgut İlaçları A.Ş.
100 Deals associated with Turgut İlaçları A.Ş.
100 Translational Medicine associated with Turgut İlaçları A.Ş.